Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old

NCT02405364 is registered in ClinicalTrials.gov with University Hospital, Toulouse as lead sponsor.

NCT NCT02405364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02405364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old
Lead sponsor
University Hospital, Toulouse
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
November 25, 2019
Enrollment
46 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma